Complete List of Approved Stem Cell & Therapies in Boao Lecheng Pilot Zone

Discover all approved stem cell and gene therapies at Boao Lecheng Pilot Zone, China’s premier medical tourism destination. From ¥16,000 to ¥480,000, treatments cover osteoarthritis, COPD, heart failure, cancer immunotherapy, and rare diseases. Explore cutting-edge regenerative medicine with transparent pricing and world-class hospitals.

Update: August 2th, 2026.

No.Therapy NameIndications / NotesPrice (RMB)
1Umbilical Cord MSC for Knee Osteoarthritis
  • Kellgren-Lawrence Grade II‑III knee osteoarthritis
  • Failed conservative treatment ≥3 months
  • Single or multiple sessions may be needed
¥36,000/single knee; ¥72,000/bilateral
2Umbilical Cord MSC for Knee Osteoarthritis
  • Same technology as #1, different hospital
  • Kellgren-Lawrence Grade II‑III knee osteoarthritis
  • Failed conservative treatment ≥3 months
¥36,000/single knee; ¥72,000/bilateral
3M‑021001 for Meniscus Injury
  • Age ≥18 years
  • Grade III meniscus injury (MRI confirmed)
  • Bone defect depth ≥2 mm, probing depth 4‑8 mm
¥80,000/single knee
4Autologous Airway Basal Stem Cells for COPD
  • Moderate‑to‑severe COPD (FEV1/FVC <70%; DLCO ≥20% <80%)
  • No tumor history, no severe comorbidities
  • Minimally invasive (cell harvest + transplantation)
¥200,000/cycle
5Airway Basal Stem Cells for Interstitial Lung Disease
  • Diagnosed ILD (including IPF, CTD‑ILD)
  • Age 40‑74 years; DLCO ≥30% <80%
  • No tumor history, no severe comorbidities
¥150,000/course
6Airway Basal Stem Cells for Bronchiectasis
  • Diagnosed bronchiectasis
  • Age 20‑80 years; DLCO ≥30% <80%
  • No tumor history, no severe comorbidities
¥150,000/course
7Menstrual Blood MSC for Pulmonary Fibrosis
  • Idiopathic pulmonary fibrosis (IPF) or other pulmonary fibrosis
  • Failed pirfenidone/nintedanib therapy
  • FVC >50% predicted
¥140,000/course (3 sessions)
8Umbilical Cord MSC for Heart Failure with Reduced EF
  • Chronic HF with LVEF ≤40%
  • NYHA Class II‑IV
  • On stable optimal medical therapy
¥60,000/session; ¥180,000/3‑session course
9Umbilical Cord MSC for Rheumatoid Arthritis
  • Moderate‑to‑severe RA (DAS28 >3.2)
  • Failed ≥2 DMARDs including methotrexate
  • Age 18‑75 years, no active infection
¥50,000/session × 4 sessions (¥200,000/course)
10MSC for Graft‑vs‑Host Disease Post‑BMT
  • Acute or chronic GVHD post‑allogeneic HSCT
  • Steroid‑resistant or steroid‑dependent
  • No HLA matching required
¥80,000/session (1‑3 sessions)
11Umbilical Cord MSC for Premature Ovarian Insufficiency
  • Diagnosed POI (FSH >25 IU/L, oligomenorrhea ≥4 months)
  • Age <40 years with fertility desire
  • AMH <1.1
¥80,000/bilateral
12Dental Pulp MSC for Periodontal Disease
  • Moderate‑to‑severe periodontitis with bone loss >50%
  • Desire to preserve natural teeth
  • Failed conventional periodontal treatment
¥59,800/tooth
13VUM02 (Umbilical Cord MSC) for Liver Cirrhosis
  • Compensated or early decompensated cirrhosis (Child‑Pugh A/B)
  • HBV‑related cirrhosis with stable antiviral therapy
  • Bridge therapy for liver transplantation
¥150,000/session; ¥450,000/3‑session course
14Menstrual Blood MSC for Decompensated Cirrhosis
  • Decompensated cirrhosis (Child‑Pugh B/C)
  • No acute gastrointestinal bleeding
  • Alternative to liver transplantation
¥150,000/course (3 injections)
15Allogeneic Hepatocyte Therapy for Liver Cirrhosis
  • Compensated or decompensated cirrhosis (Child‑Pugh A‑C)
  • Ascites, coagulopathy, or other hepatic insufficiency
  • Not suitable for or unwilling to undergo liver transplantation
¥149,000/case
16Umbilical Cord MSC for Type 2 Diabetes
  • Type 2 diabetes duration ≥5 years; HbA1c >8% on multiple regimens
  • Preserved C‑peptide secretion
  • No severe comorbidities or tumor history
¥59,800/injection; ~¥200,000/3‑injection course
17GLP‑1/FGF21 Dual‑Factor Adipose Stem Cells for T2DM
  • Age 18‑70 years with moderate‑to‑severe T2DM
  • Poor response to conventional therapy
  • No acute diabetic complications
¥360,000/course
18Allogeneic Endothelial Progenitor Cells for Critical Limb Ischemia
  • Severe lower limb ischemia (Fontaine III/IV)
  • Rest pain or foot ulcer
  • Failed or unsuitable for revascularization
¥100,000/case
19Human iPSC‑Derived Motor Neuron Precursors for ALS
  • Confirmed ALS (revised El Escorial criteria)
  • Early‑to‑mid stage with preserved ALSFRS‑R score
  • Price pending
To be announced
20Hematopoietic Stem Cell Gene Editing for β‑Thalassemia
  • Age 7‑55 years with transfusion‑dependent β‑thalassemia
  • No HLA‑matched donor available
  • CRISPR/Cas9‑based gene repair
To be announced
21RPE65 Gene Therapy for Inherited Retinal Dystrophy
  • Confirmed RPE65 biallelic mutations
  • Retinal cells still have residual function
  • AAV2 vector (Luxturna equivalent)
¥480,000/eye (¥960,000/bilateral)
22AAV Gene Therapy for Hemophilia A
  • Congenital FVIII deficiency
  • Negative AAV antibody test
  • Normal liver function
¥680,000/injection
23EBV‑Specific T‑Cell Vaccine for EBV Infection
  • EBV reactivation post‑HSCT
  • EBV‑associated PTLD post‑organ transplant
  • Congenital immunodeficiency with EBV infection
¥16,000/session × 5 sessions (¥80,000/course)
24Personalized DC Vaccine for Malignant Tumors
  • Solid tumors (lung, breast, colorectal, etc.)
  • Post‑surgery/chemo/radiotherapy adjuvant
  • Failed conventional treatment
¥150,000/dose; ¥1,050,000/7‑dose course
25Activated T Cells for Liver Cancer Recurrence Prevention
  • Post‑R0 resection of hepatocellular carcinoma
  • Normal tumor markers and no visible residual disease
  • Evaluated within 3‑6 months post‑surgery
¥100,000/session (multiple sessions may be needed)
26EBV‑Loaded DC Vaccine for EBV‑Positive Hematologic Tumors
  • EBV‑positive hematologic malignancies (mainly lymphoma)
  • Relapsed/refractory after chemotherapy
  • Combined therapy approach
¥126,000/session
27German DC Immunotherapy for Pancreatic & Colorectal Cancer
  • Pancreatic cancer or colorectal cancer
  • Specific treatment course varies by cancer type
  • High cost, individualized protocol
¥380,000/session (3 sessions for colorectal, 5 for pancreatic)
28Autologous NK Cell Therapy
  • Lung cancer patients (solid tumors)
  • Post‑surgery or post‑chemotherapy adjuvant
  • Enhanced immune surveillance
¥210,000/3 sessions
29Autologous NK Cell Therapy
  • 8 cancer types: lung, liver, gastric, colorectal, cervical, breast, ovarian, pancreatic
  • Adjuvant after primary treatment (surgery/chemo/radiotherapy)
  • Clear residual minimal disease, delay recurrence
¥49,800/session; ¥298,800/6‑session course
30Autologous NK Cell Adjuvant Immunotherapy for Solid Tumors
  • Lung, breast, gastric, colorectal, liver, pancreatic, ovarian, cervical cancer
  • Adjuvant therapy post‑surgery/chemo/radiotherapy
  • 3‑6 sessions per course
¥49,800/session (¥149,400‑¥298,800/course)

Important Notes:

  • General Requirements: Age 18‑75 years (varies by therapy), no active infections, no tumor history (unless specified), and adequate organ function.
  • Evaluation: All patients must undergo a pre‑assessment by the designated hospital. Required documents typically include CT, ultrasound, blood tests, liver/kidney function, coagulation profile, tumor markers, and discharge summary (if available).
  • Availability: Some therapies are still in the evaluation phase and may not yet be actively recruiting. Please confirm with the hospital before traveling.
  • Contact: For inquiries or to submit medical records for pre‑assessment, please email us at support@lechengmedical.com.

Disclaimer: All therapies listed are approved for clinical use within the Boao Lecheng Pilot Zone under China’s “pioneering pilot” policy. Prices and indications are subject to change. Final eligibility and treatment plans are determined by the treating hospital’s medical team.

Further reading on stem-cell safety

What the evidence does and does not show about the risks of mesenchymal stem cell therapy.